Rockville, Md. – October 12, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) will host a three-hour investor event on October 20, 2026 to review its wet age-related macular degeneration (wet AMD) gene therapy program, with topline pivotal data anticipated in the fourth quarter of 2026.

Event runs 1:00 p.m. to 4:00 p.m. ET in New York and online

The session will be held in person in New York and streamed by webcast. It will cover the clinical program for surabgene lomparvovec (sura-vec, ABBV-RGX-314), which REGENXBIO is developing in collaboration with AbbVie.

Rockville, Md. – September 24, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) reported that 60% of Dose Level 3 participants with three-year follow-up data in its Phase II ALTITUDE study achieved a greater-than-2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) after a single in-office treatment with investigational gene therapy sura-vec, with no vision-threatening events recorded among responders.

Rockville, Maryland – September 11, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) will hold fireside chats at two major investor healthcare conferences in New York this month.

REGENXBIO confirms back-to-back fireside chats on September 15 and 16

The gene therapy company will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15 at 8:30 a.m. ET, followed by the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16 at 8:30 a.m. ET. Both sessions will take place in New York, NY.